KYMERA THERAPEUTICS, INC. Increase (Decrease) in Other Operating Assets and Liabilities, Net
KYMERA THERAPEUTICS, INC. (KYMR) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $4.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was $2.16M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was -$2.15M, a 410.23% decline year-over-year.
- KYMERA THERAPEUTICS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was -$290.00K.
- KYMERA THERAPEUTICS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-06-30 was -$588.00K, a 191.73% decline year-over-year.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month |
|---|---|---|---|
| 2026-06-30 | $2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.00K 10-Q · filed 2026-08-05 | |
| 2026-03-31 | -$2.15M 10-Q · filed 2026-04-30 | ||
| 2025-09-30 | -$290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$878.00K derived: sum of 2 quarters · filed 2026-08-05 | -$184.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$588.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $106.00K 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $694.00K 10-Q · filed 2026-04-30 | ||
| 2024-09-30 | -$475.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $166.00K derived: sum of 2 quarters · filed 2025-11-04 | -$112.00K 10-Q · filed 2025-11-04 |
| 2024-06-30 | $641.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $363.00K 10-Q · filed 2025-08-11 | |
| 2024-03-31 | -$278.00K 10-Q · filed 2025-05-09 | ||
| 2023-09-30 | -$365.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$181.00K derived: sum of 2 quarters · filed 2024-10-31 | -$539.00K 10-Q · filed 2024-10-31 |
| 2023-06-30 | $184.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$174.00K 10-Q · filed 2024-08-07 | |
| 2023-03-31 | -$358.00K 10-Q · filed 2024-05-02 | ||
| 2022-09-30 | $167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $887.00K derived: sum of 2 quarters · filed 2023-11-02 | $337.00K 10-Q · filed 2023-11-02 |
| 2022-06-30 | $720.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $170.00K 10-Q · filed 2023-08-03 | |
| 2022-03-31 | -$550.00K 10-Q · filed 2023-05-04 | ||
| 2021-09-30 | -$304.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $582.00K derived: sum of 2 quarters · filed 2022-11-03 | $439.00K 10-Q · filed 2022-11-03 |
| 2021-06-30 | $886.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $743.00K 10-Q · filed 2022-08-09 | |
| 2021-03-31 | -$143.00K 10-Q · filed 2022-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |